USA flag logo/image

An Official Website of the United States Government

Aptamer-Enhanced Biorecognition Reagent System

Award Information

Agency:
Department of Defense
Branch:
Office for Chemical and Biological Defense
Award ID:
58336
Program Year/Program:
2002 / SBIR
Agency Tracking Number:
C021-0179
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
OMNISITE BIODIAGNOSTICS, INC.
101 West Sixth Street Suite 200 Austin, TX 78701
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2002
Title: Aptamer-Enhanced Biorecognition Reagent System
Agency / Branch: DOD / CBD
Contract: DAMD17-02-C-0109
Award Amount: $99,995.00
 

Abstract:

"OmniSite BioDiagnostics, Inc. (OmniSite) proposes to develop DNA Aptamers to Bacillus anthracis (nonpathogenic Sterne strain) spores and staphylococcal enterotoxin B (SEB) by the SELEX process. Aptamers are less expensive than antibodies to produce, do notrequire animal hosts for production, can be protected from nucleases, and used in a variety of assay formats to replace antibodies. In Phase I, OmniSite will compare three different detection technologies using aptamers to the two targets; 1)aptamer-electrochemiluminescence (ECL using a borrowed Origen analyzer from IGEN, Inc.), 2) aptamer-fluorescence polarization (FP using OmniSite's breadboard reader), and 3) aptamer-fluorescence resonance energy transfer (FRET using a standardspectrofluorometer). At the conclusion of Phase I, OmniSite will downselect to one detection technology based on sensitivity data, assay performance, and ease of military field use. OmniSite's CTO and principal investigator, Dr. John Bruno is a recognizedaptamer developer and innovator with numerous peer-reviewed publications in the areas of aptamers, ECL, and FRET as well as ample recent experience and SBIR awards involving aptamers and FP analysis. In Phase II, OmniSite will clone and sequence theaptamers as well as optimize and package the selected assays for facile field use with an off-the-shelf version of the chosen detector technology. The fusion of SELEX DNA Aptamer assay technology with the propos

Principal Investigator:

John G. Bruno
Chief Technical Officer
5124797732
bruno@spec.com

Business Contact:

James J. McNeal
Contracts Director
5124797732
mcneal@spec.com
Small Business Information at Submission:

Omnisite Biodiagnostics, Inc.
101 West Sixth Street, Suite 200 Austin, TX 78701

EIN/Tax ID: 742975605
DUNS: N/A
Number of Employees:
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No